



TAH3311 APIXABAN ORAL DISSOLVING FILM



TAHO
Pharmaceuticals Ltd

Copyright © TAHO Pharmaceuticals Ltd
d. All rights reserved.
www.tahopharma.com

E-mail : BD@tahopharma.com
Tel: +886 2 2659 8515
Fax: +886 2 2659 8516

3F, No.550, Ruiguang Road Neihu Dist.,
Taipei 11492, Taiwan

DISCLAIMER



This presentation and the accompanying oral commentary have been prepared by TAHO Pharmaceutical Ltd. ("TAHO" , the "Company" , "our" or "us") contains forward-looking statements about our business. These forward-looking statements do not relate strictly to historical or current facts and they may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning.

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the Taipei Securities and Exchange Commission.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company' s securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

TAHO logo are registered trademarks of TAHO Pharmaceutical Ltd. All other registered trademarks referenced herein are the property of their respective owners.

COMPANY OVERVIEW

TAHO PHARMACEUTICALS LTD.

Founded	2010
Base	Taipei, Taiwan
Focus	Drug delivery technology
Strategy	Deliver existing drugs through innovative new transdermal or transmucosal route with improved deliverability and efficacy



TRANSEPITHELIAL DELIVERY SYSTEM (TDS)



Transdermal Delivery System

- Up to several day duration
- More consistent plasma level
- No first-pass metabolism
- Highly reliable for both patients and health care providers



Transmucosal Delivery System

- No water needed
- No risk of choking
- Ideal “take-away medicine”
- Product differentiation for lifecycle management

TDS PLATFORM

ALWAYS THERE, WHEREVER and WHENEVER



**Pocket-Sized
Convenience**



**! Peel !
! Pick !
! Done !**

LEAD ASSET - TAH3311 APIXABAN ORAL DISSOLVING FILM

FIRST AND ONLY ORAL FILM FORMULATION FOR NOVEL ORAL ANTICOAGULANTS



Easy to Carry




Easy to Administer



**Improves
Compliance**

MARKET DYNAMICS FOR – ANTICOAGULANTS





Source: <https://www.gminsights.com/industry-analysis/anticoagulants-market>

A MARKET DEFINED BY APIXABAN

Apixaban (Eliquis®) dominates the anticoagulant market that's worth over \$20B¹

Eliquis® now commands >75% DOAC prescriptions, reflecting a stronghold in an entrenched yet mature market
TAH3311 offers a differentiated formulation with potential to meet key patient and provider needs unmet by existing options

Market Share Of Anti-Thrombotics




Better Medicine
Better Care


1. Grand View Market Research. 2025. TD Cowen Equity Research. Therapeutic Categories outlook - Cardiovascular. Oct. 2024. 2. Navar et al., J Am Heart Assoc. 2022; 11(22)

GLOBAL SCALE PATIENT IMPACT

Dysphagia affects more than 50% of stroke survivors, 13% remain dysphagic after 6 months
TAH3311 provides a differentiated ODF formulation, especially for patients with swallowing difficulties



PREVALENCE OF DYSPHAGIA




OLDER PEOPLE

An estimated 50–75% of care home residents have some difficulty swallowing ¹




STROKE SURVIVORS

Dysphagia affects around 50% of survivors immediately after a stroke ¹




DEMENTIA IN CARE HOMES

68% of those with Dementia in care homes show signs of dysphagia ¹




MOTOR NEURONE DISEASE

As the disease progresses, dysphagia occurs in more than 80% of people living with it ¹



CANCER

Dysphagia occurs in over 50% of patients with head and neck cancer ¹



COPD

Around 27% of people with chronic obstructive pulmonary disease will experience dysphagia ¹

TAH3311 – APIXABAN ORAL DISSOLVING FILM



! DRUG-DRUG INTERACTION



! HARD PILL TO SWALLOW



! GRINDING



! NASOGASTRIC TUBE BLOCKAGE



! CLEANING CONTAINER



**TAKE
| EASY |**



TAH3311 APIXABAN ORAL DISSOLVING FILM



NON-SWALLOW MEDICATION NEEDED

	Warfarin Tablet	ELIQUIS® Apixaban Tablet	TAH3311 Apixaban ODF
Dose Strength	1–10 mg Daily	2.5–5 mg Twice a Day	2.5–5 mg Twice a Day ✓
Feeding Tube	Yes	Yes	No ✓
Grinding & Reconstitution	Yes	Yes	No ✓


Better Medicine
Better Care

TAH3311 BIOEQUIVALENT TO ELIQUIS[®]



- ✓ Same efficacy as Eliquis[®]
- ✓ Safety profile in line with Eliquis[®]

Pivotal Studies



TAH3311 APIXABAN ORAL DISSOLVING FILM



Twice Daily Oral Film For Elderly to Prevent Stroke, DVT, PE



Easy-to-administer option



Without the need to swallow, a perfect option for patients with dysphagia



Addressing an over \$20 billion global novel anticoagulant market.



EU MAA OCT 2025



PARTNERSHIP for DRUG DELIVERY
THANK YOU !



E-mail : BD@tahopharma.com

Tel: +886 2 2659 8515

Fax: +886 2 2659 8516

Copyright © TAHO Pharmaceuticals Ltd. All rights reserved.